News

Published on 29 Jan 2025 on Investing.com

Neurocrine Biosciences director sells shares worth $21.8 million By...


Article preview image

Kevin Charles Gorman, a director at Neurocrine Biosciences Inc. (NASDAQ:NBIX), recently sold a...

NASDAQ.NBIX price evolution

Want to become a better investor?

Start tracking your investments with Statfolio

Sign up for free
Related News
Neurocrine (NBIX): Among Top Insider Stock Buys And Sells In January

We recently published a list of 10 Top Insider Stock Buys And Sells In January. In this article, ...

Insider Monkey · via Yahoo Finance 18 Feb 2025

Neurocrine Biosciences' SWOT analysis: navigating growth amid market shifts By...

Neurocrine Biosciences' SWOT analysis: navigating growth amid market shifts

Investing.com 18 Feb 2025

Neurocrine Biosciences chief commercial officer sells $251,426 in stock By...

Eric Benevich, the Chief Commercial Officer of Neurocrine Biosciences Inc (NASDAQ:NBIX), recently...

Investing.com 14 Feb 2025

Neurocrine Biosciences' chief corporate affairs officer sells shares worth...

David W. Boyer, Chief Corporate Affairs Officer at Neurocrine Biosciences Inc. (NASDAQ:NBIX),...

Investing.com 14 Feb 2025

Neurocrine Biosciences CEO sells shares for $298,907 By Investing.com

SAN DIEGO—Gano Kyle, the Chief Executive Officer of Neurocrine Biosciences Inc. (NASDAQ:NBIX), a...

Investing.com 14 Feb 2025

Neurocrine Biosciences director Sherwin sells $1.6m in stock By Investing.com

SAN DIEGO—Stephen A. Sherwin, a director at Neurocrine Biosciences Inc. (NASDAQ:NBIX), a $11.4...

Investing.com 14 Feb 2025

Should You Invest in the SPDR S&P Biotech ETF (XBI)?

This ETF has heaviest allocation in the Healthcare sector--about 100% of the portfolio. Looking a...

Zacks · via Yahoo Finance 3 Feb 2025

Insider Activity Recap: Wednesday's Top Buys and Sells in US Stocks By...

Insider Activity Recap: Wednesday's Top Buys and Sells in US Stocks

Investing.com 30 Jan 2025

Neurocrine Biosciences director sells shares worth $21.8 million By...

Kevin Charles Gorman, a director at Neurocrine Biosciences Inc. (NASDAQ:NBIX), recently sold a...

Investing.com 29 Jan 2025

Neurocrine Obtains Exclusive Rights For Depression Drug, Takeda Reacquires Japan...

On Monday, Neurocrine Biosciences, Inc. (NASDAQ:NBIX) amended its agreement with Takeda...

Benzinga · via AOL 28 Jan 2025